

QUALITY OF CARE IMPROVEMENT IN METASTATIC BREAST CANCER PATIENTS



Request for Proposals (RFP) Release Date: September 4, 2020

The *Sharing Progress in Cancer Care* (SPCC) and *Pfizer Global Medical Grants* (Pfizer) are proud to announce a new grant opportunity seeking proposals in support of improving care of metastatic breast cancer (MBC) patients in Europe.

The intent of this RFP is to encourage the submission of proposals describing concepts and ideas to improve the quality of metastatic care in health systems, cancer care centers or networks.

This RFP is open to investigators from European institutions and networks (members or not of OECI) will be considered as well as professional societies and patient advocacy groups.

Areas of interest

- 1) Optimal treatment strategies for patients with MBC based on patient and tumor characteristics and genetic risk addressing treatment disparities with respect to age/socioeconomic background or setting i.e. patients in a remote setting without access to a reference cancer center/hospital or education level.
- 2) Delivering optimal treatment regardless of physician disciplines and wherever there is a point of MBC patients contact i.e. primary care (gynaecologists, surgeons).
- 3) Leveraging a multi-disciplinary team and approach to improve patient quality of MBC delivery of care.
- 4) Therapy management.
- 5) Health care professionals, healthcare managers and policymaker education in terms of outcomes research (assessment of QOL, caregiver perspective), assessment of treatment options vs healthcare systems sustainability in order to optimize MBC treatment strategies for patients. This can include incorporation of new technologies to enhance the quality of delivery of healthcare services to MBC patients.
- 6) Patient education, shared treatment goals, and engagement in decision making.
- 7) Patient adherence with MBC treatment.
- 8) Patient reported outcomes in MBC patients.

Monetary Range of Grant Applications

- A total of approximately \$1.5 Million USD is available for award.
- Individual projects requesting up to \$250,000 USD will be considered; smaller, lower-cost projects are also strongly encouraged.
- Applications will be reviewed, evaluated and selected by an independent review panel led by the SPCC.
- Awards to successful applicants will be provided by Pfizer.

Letter of intent due date: November 4, 2020

To review the full details of the RFP please go to the competitive grants information available on the SPCC website (www.spcc.net/en/projects) or Pfizer Competitive grants website (www.pfizer.com/competitive-grants)